Possible role of adrenomedullin and nitric oxide in major depression

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 46, Issue , 2013, Pages 120-125

  Akpinar, Abdullah ^a   Yaman, Gozde Bacik ^a   Demirdas, Arif ^a   Onal, Suleyman ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Adrenomedullin; Major depression; Nitric oxide; Psychomotor retardation

Indexed keywords

ADRENOMEDULLIN; NITRIC OXIDE;

ADRENOMEDULLIN BLOOD LEVEL; ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DSM-IV; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NITRIC OXIDE BLOOD LEVEL; PROTEIN FUNCTION; PSYCHOMOTOR RETARDATION; STRUCTURED INTERVIEW;

ADM; ADRENOMEDULLIN; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CGMP; CNS; CSF; CYCLIC GUANOSINE MONOPHOSPHATE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS, FOURTH EDITION; DSM-IV; HAMILTON'S 17-ITEM DEPRESSION RATING SCALE; HDRS; HPA; HYPOTHALAMUS PITUITARY ADRENAL; MAJOR DEPRESSION; MD; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NO; NOS; PSYCHOMOTOR RETARDATION; SE; STANDARD ERROR;

ADRENOMEDULLIN; ADULT; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE;

EID: 84881237732     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.07.003     Document Type: Article

References (61)

1. Akdemir A., Türkçapar M.H., Orsel S.D., Demirergi N., Dag I., Ozbay M.H. Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale. Compr Psychiatry 2001, 42:161-165.
2. Akyol O., Zoroglu S.S., Armutcu F., Sahin S., Gurel A. Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In Vivo 2004, 18:377-390.
3. Armstead W.M., Kiessling J.W., Bdeir K., Kofke W.A., Vavilala M.S. Adrenomedullin prevents sex-dependent impairment of autoregulation during hypotension after piglet brain injury through inhibition of ERK MAPK upregulation. J Neurotrauma 2010, 27:391-402.
4. Bartus K., Pigott B., Garthwaite J. Cellular targets of nitric oxide in the hippocampus. PLoS One 2013, 8:e57292.
5. Bernstein H.G., Stanarius A., Baumann B., Henning H., Krell D., Danos P., et al. Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 1998, 83:867-875.
6. Brown E.S., Rush A.J., McEwen B.S. Hippocampal remodeling and damage by corticosteroids: implications for mood disorders. Neuropsychopharmacology 1999, 21:474-484.
7. Buyukdura J.S., McClintock S.M., Croarkin P.E. Psychomotor retardation in depression: biological underpinnings, measurement, and treatment. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:395-409.
8. Ceylan N.O., Cimenci I.G., Kilincaslan A., Feridun Bulbul F., Savas H.A. Alterations in plasma nitric oxide level and arginase activity during the treatment of bipolar depressive episode. J Mood Disord 2011, 1:1-6.
9. Chen L., Kis B., Hashimoto H., Busija D.W., Takei Y., Yamashita H., et al. Adrenomedullin 2 protects rat cerebral endothelial cells from oxidative damage in vitro. Brain Res 2006, 1086:42-49.
10. Chopra K., Kumar B., Kuhad A. Pathobiological targets of depression. Expert Opin Ther Targets 2011, 15:379-400.
11. Chrapko W.E., Jurasz P., Radomski M.W., Lara N., Archer S.L., Le Mellédo J.M. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 2004, 56:129-134.
12. De Winter R.F., Van Hemert A.M., DeRijk R.H., Zwinderman K.H., Frankhuijzen-Sierevogel A.C., Wiegant V.M., et al. Anxious-retarded depression: relation with plasma vasopressin and cortisol. Neuropsychopharmacology 2003, 28:140-147.
13. Dhir A., Kulkarni S.K. Nitric oxide and major depression. Nitric Oxide 2011, 24:125-131.
14. Di Massimo C., Scarpelli P., Di Lorenzo N., Caimi G., di Orio F., Ciancarelli M.G. Impaired plasma nitric oxide availability and extracellular superoxide dismutase activity in healthy humans with advancing age. Life Sci 2006, 78:1163-1167.
15. Díaz E., Silva M., Israel A. Role of brain dopaminergic system in the adrenomedullin-induced diuresis and natriuresis. Pharmacol Res 2003, 48:489-496.
16. Eguchi S., Hirata Y., Kano H., Sato K., Watanabe Y., Watanabe T.X., et al. Specific receptors for adrenomedullin in cultured rat vascular smooth muscle cells. FEBS Lett 1994, 340:226-230.
17. Finkel M.S., Laghrissi-Thode F., Pollock B.G., Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996, 32:653-658.
18. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV clinical version (SCID-I/CV) 1997, 7 American Psychiatric Press, Washington (DC).
19. García R.G., Zarruk J.G., Barrera C., Pinzón A., Trillos E., Arenas W.D., et al. Plasma nitrate levels and flow-mediated vasodilation in untreated major depression. Psychosom Med 2011, 73:344-349.
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
21. Herken H., Akyol O., Yilmaz H.R., Tutkun H., Savas H.A., Ozen M.E., et al. Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase in patients with panic disorder: alterations by antidepressant treatment. Hum Psychopharmacol 2006, 21:53-59.
22. Herken H., Gurel A., Selek S., Armutcu F., Ozen M.E., Bulut M., et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007, 38:247-252.
23. Hinson J.P., Kapas S. The role of endothelial cell products in the regulation of adrenocortical function: actions of endothelin, nitric oxide, adrenomedullin and PAMP. Horm Metab Res 1998, 30(6-7):334-340.
24. Hinson J.P., Kapas S., Smith D.M. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000, 21:138-167.
25. Honda M., Nakagawa S., Hayashi K., Kitagawa N., Tsutsumi K., Nagata I., et al. Adrenomedullin improves the blood-brain barrier function through the expression of claudin-5. Cell Mol Neurobiol 2006, 26:109-118.
26. Ichiki Y., Kitamura K., Kangawa K., Kawamoto M., Matsuo H., Eto T. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett 1994, 24(338):6-10.
27. Ji S.M., Xue J.M., Wang C., Su S.W., He R.R. Adrenomedullin reduces intracellular calcium concentration in cultured hippocampal neurons. Sheng Li Xue Bao 2005, 57:340-345.
28. Joca S.R., Guimarães F.S. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology (Berl) 2006, 185:298-305.
29. Kahl K.G., Bens S., Ziegler K., Rudolf S., Kordon A., Dibbelt L., et al. Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology 2009, 34:353-357.
30. Karababa F., Yesilova Y., Turan E., Selek S., Altun H., Selek S. Impact of depressive symptoms on oxidative stress in patients with psoriasis. Redox Rep 2013, 18:51-55.
31. Kaster M.P., Ferreira P.K., Santos A.R., Rodrigues A.L. Effects of potassium channel inhibitors in the forced swimming test: possible involvement of l-arginine-nitric oxide-soluble guanylate cyclase pathway. Behav Brain Res 2005, 165:204-209.
32. Kastin A.J., Akerstrom V., Hackler L., Pan W. Adrenomedullin and the blood-brain barrier. Horm Metab Res 2001, 33:19-25.
33. Kaye N.S. Is your depressed patient bipolar?. J Am Board Fam Pract 2005, 18:271-281.
34. Keser A., Balkan B., Gozen O., Kanit L., Pogun S. Hippocampal neuronal nitric oxide synthase (nNOS) is regulated by nicotine and stress in female but not in male rats. Brain Res 2011, 1368:134-142.
35. Kim Y.K., Paik J.W., Lee S.W., Yoon D., Han C., Lee B.H. Increased plasma nitric oxide level associated with suicide attempt in depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1091-1096.
36. Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S., Matsuo H., et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993, 192:553-560.
37. Leonard B.E. Inflammation, depression and dementia: are they connected?. Neurochem Res 2007, 32:1749-1756.
38. Lin A.M., Kao L.S., Chai C.Y. Involvement of nitric oxide in dopaminergic transmission in rat striatum: an in vivo electrochemical study. J Neurochem 1995, 65:2043-2049.
39. MacQueen G., Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research?. Mol Psychiatry 2011, 16:252-264.
40. McDonald E.M., Mann A.H., Thomas H.C. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet 1987, 2(8569):1175-1178.
41. Miyamoto N., Tanaka R., Shimosawa T., Yatomi Y., Fujita T., Hattori N., et al. Protein kinase A-dependent suppression of reactive oxygen species in transient focal ischemia in adrenomedullin-deficient mice. J Cereb Blood Flow Metab 2009, 29:1769-1779.
42. Miyashita K., Itoh H., Arai H., Suganami T., Sawada N., Fukunaga Y., et al. The neuroprotective and vasculo-neuro-regenerative roles of adrenomedullin in ischemic brain and its therapeutic potential. Endocrinology 2006, 147(4):1642-1653.
43. Ohkuma S., Katsura M.J. Nitric oxide and peroxynitrite as factors to stimulate neurotransmitter release in the CNS. Prog Neurobiol 2001, 64:97-108.
44. Ozkurkcugil A., Aydemir O., Yildiz M., Esen Danaci{dotless} A., Koroglu E. Structured clinical interview for DSM-IV (SCID IV), Turkish version. J Drug Treat 1999, 12:233-236.
45. Papageorgiou C., Grapsa E., Christodoulou N.G., Zerefos N., Stamatelopoulos S., Christodoulou G.N. Association of serum nitric oxide levels with depressive symptoms: a study with end-stage renal failure patients. Psychother Psychosom 2001, 70:216-220.
46. Rejdak K., Petzold A., Sharpe M.A., Smith M., Keir G., Stelmasiak Z., et al. Serum and urine nitrate and nitrite are not reliable indicators of intrathecal nitric oxide production in acute brain injury. J Neurol Sci 2003, 208:1-7.
47. Richards A.M., Nicholls M.G., Lewis L., Lainchbury J.G. Adrenomedullin. Clin Sci (Lond) 1996, 91:3-16.
48. Savas H.A., Herken H., Yürekli M., Uz E., Tutkun H., Zoroǧlu S.S., et al. Possible role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology 2002, 45:57-61.
49. Selek S., Savas H.A., Gergerlioglu H.S., Bulbul F., Uz E., Yumru M. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord 2008, 107:89-94.
50. Selley M.L. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. J Affect Disord 2004, 80:249-256.
51. Shan J., Krukoff T.L. Intracerebroventricular adrenomedullin stimulates the hypothalamic pituitary adrenal axis, the sympathetic nervous system and production of hypothalamic nitric oxide. J Neuroendocrinol 2001, 13:975-984.
52. Shelton R.C., Claiborne J., Sidoryk-Wegrzynowicz M., Reddy R., Aschner M., Lewis D.A., et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011, 16:751-762.
53. Suzuki E., Yagi G., Nakaki T., Kanba S., Asai M. Elevated plasma nitrate levels in depressive states. J Affect Disord 2001, 63:221-224.
54. Talarowska M., Gałecki P., Maes M., Orzechowska A., Chamielec M., Bartosz G., et al. Nitric oxide plasma concentration associated with cognitive impairment in patients with recurrent depressive disorder. Neurosci Lett 2012, 510:127-131.
55. Van Londen L., Kerkhof G.A., Van Den Berg F., Goekoop J.G., Zwinderman K.H., Frankhuijzen-Sierevogel A.C., et al. Plasma arginine vasopressin and motor activity in major depression. Biol Psychiatry 1998, 43:196-204.
56. Wagner J., Tennen H., Mansoor G., Abbott G. Endothelial dysfunction and history of recurrent depression in postmenopausal women with Type 2 diabetes: a case-control study. J Diabetes Complications 2009, 23:18-24.
57. Xia C.F., Yin H., Borlongan C.V., Chao J., Chao L. Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis. Exp Neurol 2006, 197:521-530.
58. Xu Y., Krukoff T.L. Adrenomedullin stimulates nitric oxide production from primary rat hypothalamic neurons: roles of calcium and phosphatases. Mol Pharmacol 2007, 72:112-120.
59. Yuksel S., Akbay A., Yurekli M. Contribution of adrenomedullin to homeostatic response to cold stress in rat model. Pathophysiology 2002, 8:243-247.
60. Zoroglu S.S., Herken H., Yürekli M., Uz E., Tutkun H., Savaş H.A., et al. The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J Psychiatr Res 2002, 36:309-315.
61. Zoroǧlu S.S., Yürekli M., Meram I., Söǧüt S., Tutkun H., Yetkin O., et al. Pathophysiological role of nitric oxide and adrenomedullin in autism. Cell Biochem Funct 2003, 21:55-60.